A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Conditions:   Lung Cancer;   Non Small Cell Lung Cancer Interventions:   Drug: LMB-100;   Drug: pembrolizumab;   Diagnostic Test: Mesothelin Expression Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials